Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients with Moderate to Severe Plaque Psoriasis: Post-hoc Results from Five Phase 3/3b Trials. J of Skin [Internet]. 2024 Jan. 16 [cited 2025 Jul. 22];8(1):s303. Available from: https://skin.dermsquared.com/skin/article/view/2436